Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	15646-46-5
Formula :	C₁₂H₁₁NO₃
M.W :	217.22
SMILES Code :	O=C(OC(C1=CC=CC=C1)=N2)C2=COCC
MDL No. :	MFCD00003204

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H317
Precautionary Statements:	P280

Nrf2 (+/+) and Nrf2 (−/−) mouse embryonic fibroblasts (MEFs)	10 µM	24 hours	To evaluate the effect of oxazolone on transcriptional activation of Th2 cytokines, results showed that NRF2 suppresses oxazolone-induced production of Th2 cytokines.	Antioxidants (Basel). 2020 Sep 7;9(9):834
HaCaT cells	50 µM	24 hours	To evaluate the effects of Oxazolone on oxidative stress and inflammatory responses in HaCaT cells. Results showed that Oxazolone significantly increased intracellular ROS levels and inflammatory cytokine expression, while D. dasycarpus and P. cicadae effectively reduced these effects.	Antioxidants (Basel). 2018 Jun 15;7(6):77
Sheep red blood cells (SRBC)	0.163 mg/ml	30 minutes	To measure haemagglutinating antibody to oxazolone in mice, results showed that pooled sera from immunized mice had a haemagglutination titre of 27–29, while sera from unimmunized mice had no detectable antibody.	Immunology. 1972 Sep;23(3):289-98

BALB/c mice	Oxazolone-induced atopic dermatitis model	Topical application on ears	0.1% oxazolone solution	Every 48 hours for 10 times	To evaluate the oxazolone-induced atopic dermatitis model and its therapeutic effects. Oxazolone-induced dermatitis showed ear swelling, skin inflammation, and elevated immunoglobulin levels. PFS treatment significantly alleviated these symptoms.	Mediators Inflamm. 2020 Oct 15;2020:4346367
Balb/c mice	Oxazolone-induced atopic dermatitis model	Topical application	0.2 mg/mouse	Ear thickness was measured every five days for 24 days	To evaluate the inhibitory effect of cardamonin on oxazolone-induced atopic dermatitis, results showed that cardamonin significantly suppressed oxazolone-induced inflammation and Th2 cytokine production.	Antioxidants (Basel). 2020 Sep 7;9(9):834
BALB/c mice	Atopic dermatitis model	Topical application on the ear	0.8% for sensitization, 0.4% for challenge	After 1 week of sensitization, every second day for a total of 5 times	To evaluate the effect of cesarean section and vaginal delivery on atopic dermatitis in mice. Results showed that CS-delivered mice and mice inoculated with human CS-GM had higher serum IgE concentrations, but the severity of dermatitis was similar among all groups.	Gut Microbes. 2023 Dec;15(2):2271151
BALB/c mice	Oxazolone-induced AD-like skin inflammation model	Topical administration	1% OXA	Once daily for 1 week	To evaluate the effect of A63 extract on OXA-induced AD-like skin inflammation. Results showed that A63 extract significantly reduced epidermal thickness and inflammatory cell infiltration, and downregulated the expression of AD gene markers.	Molecules. 2022 Apr 25;27(9):2751
BALB/c mice	Oxazolone-induced AD-like lesion model	Topical application to ear surfaces	1% Oxazolone	Once daily for 7 days, then every 2 days for 3 weeks	To evaluate Oxazolone-induced AD-like lesions. Oxazolone treatment increased ear thickness and epidermal thickness and increased mast cell infiltration. DCE significantly improved these symptoms.	Nutrients. 2022 Oct 27;14(21):4521
Mice	Oxazolone colitis model	Intrarectal administration	1.5% oxazolone	Single dose, assessed after 3 days	To evaluate the role of IL-33 and ST2 in oxazolone colitis. Results showed increased colitis severity, decreased goblet cells, and impaired epithelial barrier function in IL-33?/? and ST2?/? mice.	Inflamm Bowel Dis. 2015 Dec;21(12):2737-46
Mice	Mouse lymph node model	Topical application	10%	Single dose	To study the effects of antigenic stimulation on the expansion of T-cell-dependent areas in lymph nodes. Results showed rapid expansion of T-cell-dependent areas after Oxazolone stimulation, but the increase in HEV lagged behind the expansion of the T-cell area.	Immunology. 1990 Nov;71(3):423-7
BALB/c mice	Oxazolone-induced intestinal colitis model	Intrarectal administration	20 mg/kg	Once daily for six consecutive days	To investigate the effects of exogenous CRAMP on oxazolone-induced colitis, 20 mg/kg CRAMP significantly improved body weight regain, reduced colon weight/length ratio, and ameliorated colon tissue inflammation	Hum Vaccin Immunother. 2018 Jan 2;14(1):146-158
Mice	Oxazolone-induced contact hypersensitivity model	Topical application	25 μl (100 mg/mL) for sensitization, 10 μl (10 mg/mL) for challenge	Sensitization for two days, single challenge	To investigate the interaction of Breg cells, mast cells, and ILC2s in oxazolone-induced contact hypersensitivity, results showed that mast cells maintain Breg cell numbers via IL-5, and Breg cells suppress ILC2 activity via IL-10, thereby alleviating skin inflammation.	Sci Adv. 2019 Jul 17;5(7):eaav8152
C57BL/6J mice	Contact hypersensitivity model	Topical application	3% OX for sensitization, 1% OX for challenge	Single sensitization, single challenge after 5 days	To investigate basophil migration in the oxazolone-induced contact hypersensitivity model. Results showed a decrease in peripheral blood basophil numbers one day after challenge, but not after 2 days, reflecting supplementation from the bone marrow.	Front Immunol. 2022 Sep 29;13:1014924
C57BL/6 mice	Oxazolone-induced colitis model	Catheter injection	3% Oxa solution	Single injection	To study the Oxazolone-induced colitis model, which mimics the type 2 immune response in ulcerative colitis (UC) patients. Results showed that Oxazolone-induced colitis mice exhibited significant inflammatory responses.	Front Immunol. 2022 Jan 18;12:783806
CBA mice	Contact sensitivity model	Skin application	3% oxazolone	Single dose, tested after 7 days	To study contact sensitivity to oxazolone in mice, results showed that antibodies of IgM, IgG1, IgG2a, and IgG2b classes were detected in sera from immunized mice, while low-avidity antibodies were detected in sera from unimmunized mice.	Immunology. 1972 Sep;23(3):289-98
BALB/c mice	Oxazolone-induced colitis model	Abdominal application and intrarectal administration	3% oxazolone for abdominal sensitization, 1% oxazolone for intrarectal administration	Intrarectal administration 7 days after sensitization, experiment lasted for 3 days	To investigate the role of IL-4Rα signaling in specific cell types (e.g., intestinal epithelial cells, smooth muscle cells, and macrophages/neutrophils) in oxazolone colitis. Results showed that IL-4Rα signaling in these cell types plays a redundant role in acute oxazolone colitis.	Mediators Inflamm. 2020 Jan 17;2020:4361043
CBA mice	Contact sensitization model	Topical application	3% Oxazolone solution	Weekly	To investigate the effect of contact sensitization and boosting on the production of Oxazolone-specific cytophilic antibodies	Immunology. 1974 Oct;27(4):563-76
Sprague Dawley rats	Oxazolone-induced ulcerative colitis model	Topical application on the back and anal injection	30 mg/mL	One-time topical application on the back, followed by anal injection five days later	Evaluate the effect of Oxazolone-induced ulcerative colitis model, results showed Oxazolone successfully induced colitis symptoms, including colon shortening, splenomegaly, inflammatory cell infiltration, and tissue damage.	Molecules. 2019 Dec 24;25(1):76
Hairless male ICR mice	Oxazolone-induced allergic contact dermatitis model	Topical application	5% (initial sensitization) and 1% (subsequent challenges)	Initial sensitization once, followed by challenges every other day for 10 days	To assess the effects of Oxazolone on inflammatory responses and skin damage in mice. Results showed that Oxazolone significantly increased skin thickness and inflammatory cell infiltration, while D. dasycarpus and P. cicadae significantly alleviated these effects.	Antioxidants (Basel). 2018 Jun 15;7(6):77
BALB/c mice	Oxazolone-induced atopic dermatitis-like skin lesions	Topical application	5% OX for sensitization, 0.5% OX for challenge	Twice a week after sensitization for three weeks	To evaluate the severity of oxazolone-induced atopic dermatitis-like skin lesions, including increased ear thickness and weight, thickening of the epidermis and dermis, mast cell infiltration, and elevated serum IgE levels. Results showed that oxazolone successfully induced atopic dermatitis-like skin lesions.	Mar Drugs. 2022 Oct 26;20(11):669
C57BL/6 mice	Oxazolone-induced contact dermatitis model	Topical application	50 μl 2% OXA for sensitization, 25 μl 1% OXA for challenge	Sensitization once, challenge once, evaluated after 24 hours	To investigate the role of the LTB4–BLT1 axis in Oxazolone-induced contact dermatitis. Results showed that BLT1 deficiency or blockade of LTB4 and BLT1 by antagonists significantly reduced ear swelling and skin-infiltrating neutrophils and CD8+ T cells.	Immunology. 2015 Sep;146(1):50-8
Mice	Intestinal-specific VDR knockout mice	Rectal administration	5μl/g	Single dose, observed for 5 days	To investigate the protective effect of intestinal-specific VDR knockout on oxazolone-induced colitis, results showed that VDR knockout alleviated the severity of colitis	Cell Death Dis. 2020 Jun 15;11(6):461
Wistar rats	Oxazolone-induced ulcerative colitis	Intracolonic administration	7.5 mg/mL	Single dose	Induction of ulcerative colitis model to study the therapeutic effects of β-glucan and/or Celastrol	Redox Rep. 2022 Dec;27(1):60-69
Wistar albino male rats	Oxazolone-induced ulcerative colitis model	Rectal administration	7.5 mg/mL, 1.1 mL/rat	Single dose	Induction of ulcerative colitis model to study the moderating effects of β-glucan and/or aldose reductase inhibitor Fidarestat on the gut microbiome/mitochondrial axis.	Int J Mol Sci. 2023 Jan 31;24(3):2711
SJL/J female mice	Oxazolone-induced colitis model	Intraperitoneal injection	8, 2, or 0.5 mg/kg	Once every 2 days, for a total of five doses	To evaluate the efficacy of the bifunctional IL-4/IL-13 antagonist in the oxazolone-induced colitis model. Results showed that the antagonist reduced body weight loss, maintained colon length, minimized gains in colon weight, and reduced disease activity index.	Immunology. 2014 Nov;143(3):416-27

{[proInfo.proName]}

CAS No.: 15646-46-5

{[proInfo.proName]}

CAS No.: 15646-46-5

Alternative Products

Product Details of Oxazolone

Safety of Oxazolone

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed